Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) provided a significant update on its clinical trials, notably AIPAC and TACTI-002, reporting that AIPAC has reached 72% of events and TACTI-002 is progressing well with 54 patients enrolled. New data from these studies is expected to be presented at ASCO in June 2021. The TACTI-003 trial, evaluating efti with pembrolizumab, aims to start mid-2021, while the company maintains a robust financial position with a cash runway extending into 2023.
Immutep Limited (NASDAQ: IMMP) announced new data from its TACTI-002 and INSIGHT-004 studies, to be presented during the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting from June 4-8. This includes three poster presentations focused on the efficacy of eftilagimod alpha in combination with pembrolizumab and avelumab across various cancers. The abstracts will be available on May 19, with further data shared in a subsequent webcast. These studies are pivotal in advancing LAG-3 immunotherapy treatments for cancer.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant strides in its clinical trials, successfully dosing the final HNSCC patient in Stage 2 of Part C of the TACTI-002 study. Recruitment has begun for both first and second line NSCLC patients in the trial. The Phase II EAT COVID trial has also advanced into its randomized segment. As of March 31, 2021, the company reported a strong cash position of $51.7 million, providing a runway beyond 2022. The company has bolstered intellectual property protections for its lead candidate, eftilagimod alpha, with a new patent granted.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a cash rebate of A$1,155,055 from the Australian Federal Government’s R&D tax incentive program. This rebate pertains to expenses from eligible R&D activities during the 2020 fiscal year, primarily focusing on the TACTI-mel and TACTI-002 clinical studies involving eftilagimod alpha (efti). With approval from AusIndustry, Immutep’s Australian and overseas activities related to TACTI-002 are eligible for this tax incentive for three years, using the funds to further its clinical trials.
Immutep Limited (NASDAQ: IMMP) announced that its lead candidate, eftilagimod alpha (efti), has received FDA Fast Track designation for first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This designation is based on promising data from its Phase II TACTI-002 trial, showing a 36% overall response rate. Additionally, preparations for the new Phase IIb TACTI-003 trial are advancing. Fast Track designation allows Immutep expedited development and review processes with the FDA, potentially leading to quicker patient access.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of patent number EP3317301 by the European Patent Office, covering combination therapies involving its LAG525 antibody and spartalizumab for cancer treatment. This patent, co-owned with Novartis AG, extends until July 28, 2036. LAG525 is evaluated in several clinical trials by Novartis, and Immutep stands to receive milestone and royalty payments from its development.
Immutep Limited announced that CEO Marc Voigt will participate in the Inaugural Emerging Growth Virtual Conference on March 17-19, 2021. Voigt is scheduled for a fireside chat with analyst Jason McCarthy on March 19 at 9:30 am EST. The conference features discussions with C-suite executives and live Q&A sessions.
Immutep focuses on developing immunotherapy treatments for cancer and autoimmune diseases, with their lead product candidate being eftilagimod alpha. The company is listed on the ASX (IMM) and NASDAQ (IMMP).
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced a new Phase IIb trial named TACTI-003 to evaluate the combination of its lead product eftilagimod alpha with MSD’s KEYTRUDA® in treating first-line head and neck squamous cell carcinoma (HNSCC). Expected to enroll its first patient by mid-2021, the trial will involve around 160 patients and aim to assess safety and efficacy compared to KEYTRUDA alone. HNSCC is a prevalent cancer with significant unmet medical needs, highlighting the importance of this study.
Immutep Limited (NASDAQ: IMMP) has announced the grant of a new patent (10,940,181) by the U.S. Patent & Trade Mark Office for methods of treating cancer using its lead immunotherapy candidate, eftilagimod alpha (efti), combined with a PD-1 pathway inhibitor such as pembrolizumab or nivolumab. The patent, valid until January 20, 2036, enhances the company's intellectual property and supports ongoing investments in clinical development. This announcement follows the grant of a parent patent in December 2020 and indicates further developments are underway, including additional divisional applications.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced an expansion of Part B in its TACTI-002 Phase II trial for second line Non-Small Cell Lung Cancer (NSCLC), following a positive safety and efficacy review. The study, conducted in collaboration with Merck & Co., aims to evaluate the combination of efti and KEYTRUDA® in multiple cancer types. Additional patient recruitment will include 13 more NSCLC patients in Stage 2 of Part B. This trial represents an opportunity to advance treatment options in oncology and reflects Immutep's commitment to immunotherapy development.